ALRN
Price:
$1.88
Market Cap:
$40.73M
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed...[Read more]
Industry
Biotechnology
IPO Date
2017-06-29
Stock Exchange
NASDAQ
Ticker
ALRN
According to Aileron Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -46.89%. This represents a change of 39.08% compared to the average of -33.71% of the last 4 quarters.
The mean historical ROE of Aileron Therapeutics, Inc. over the last ten years is -107.25%. The current -46.89% ROE has changed -56.28% with respect to the historical average. Over the past ten years (40 quarters), ALRN's ROE was at its highest in in the June 2017 quarter at 4.08%. The ROE was at its lowest in in the March 2016 quarter at -116.75%.
Average
-107.25%
Median
-124.13%
Minimum
-228.43%
Maximum
16.21%
Discovering the peaks and valleys of Aileron Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 240.34%
Maximum Annual ROE = 16.21%
Minimum Annual Increase = -6225.54%
Minimum Annual ROE = -228.43%
Year | ROE | Change |
---|---|---|
2023 | -228.43% | 57.49% |
2022 | -145.04% | 147.16% |
2021 | -58.68% | -67.29% |
2020 | -179.39% | 0.03% |
2019 | -179.35% | 11.43% |
2018 | -160.95% | 240.34% |
2017 | -47.29% | -391.76% |
2016 | 16.21% | 18.72% |
2015 | 13.65% | -113.23% |
2014 | -103.22% | -6225.54% |
The current ROE of Aileron Therapeutics, Inc. (ALRN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-144.05%
5-year avg
-158.18%
10-year avg
-107.25%
Aileron Therapeutics, Inc.’s ROE is greater than Applied Molecular Transport Inc. (-131.59%), greater than Catalyst Biosciences, Inc. (-63.14%), less than Bio-Path Holdings, Inc. (2.62%), greater than Benitec Biopharma Inc. (-60.28%), greater than Artelo Biosciences, Inc. (-26.25%), greater than Histogen Inc. (-80.69%), greater than Curis, Inc. (-924.75%), greater than Timber Pharmaceuticals, Inc. (-209.49%), less than Evelo Biosciences, Inc. (91.90%), greater than Aptinyx Inc. (-96.38%), greater than Magenta Therapeutics, Inc. (-14.27%), greater than ABVC BioPharma, Inc. (-98.40%), greater than Neoleukin Therapeutics, Inc. (-8.54%), greater than CytomX Therapeutics, Inc. (-41.34%), greater than Assembly Biosciences, Inc. (-121.46%), greater than Instil Bio, Inc. (-37.44%), greater than Nuvation Bio Inc. (-108.68%), greater than First Wave BioPharma, Inc. (-17.85%), greater than Salarius Pharmaceuticals, Inc. (-140.30%), greater than SAB Biotherapeutics, Inc. (-94.37%), less than Vaccinex, Inc. (1.93%), greater than GeoVax Labs, Inc. (-809.91%),
Company | ROE | Market cap |
---|---|---|
-131.59% | $11.01M | |
-63.14% | $19.42M | |
2.62% | $2.84M | |
-60.28% | $274.45M | |
-26.25% | $3.68M | |
-80.69% | $85.44K | |
-924.75% | $30.48M | |
-209.49% | $1.18M | |
91.90% | $7.59K | |
-96.38% | $0 | |
-14.27% | $42.44M | |
-98.40% | $6.46M | |
-8.54% | $8.20M | |
-41.34% | $84.13M | |
-121.46% | $96.42M | |
-37.44% | $139.92M | |
-108.68% | $866.66M | |
-17.85% | $5.99M | |
-140.30% | $2.02M | |
-94.37% | $36.36M | |
1.93% | $10.24M | |
-809.91% | $22.03M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aileron Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aileron Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Aileron Therapeutics, Inc.'s ROE?
How is the ROE calculated for Aileron Therapeutics, Inc. (ALRN)?
What is the highest ROE for Aileron Therapeutics, Inc. (ALRN)?
What is the 3-year average ROE for Aileron Therapeutics, Inc. (ALRN)?
What is the 5-year average ROE for Aileron Therapeutics, Inc. (ALRN)?
How does the current ROE for Aileron Therapeutics, Inc. (ALRN) compare to its historical average?